UCB's Zogenix Bet Pays Out Quickly With Fresh Fintepla Approval
Second Indication For Rare Epilepsy Potential Blockbuster
Gaining approval for Fintepla in Lennox-Gastaut syndrome, on top of an earlier green light in Dravet, puts the Belgian group in a strong position to compete with Jazz’s Epidiolex.
